Trends in the use of immune checkpoint inhibitors for non-small cell lung cancer in the Netherlands from 2016 to 2020, a national cancer registry analysis
Research Square
2024
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Introduction This study aims to describe immune checkpoint inhibitors’ (ICIs) prescription trends for Non-small cell lung cancer (NSCLC) in the Netherlands and their association with survival. We compared our results with data from randomized controlled trials (RCTs). Methods We analyzed ICIs prescription trends and their relationship with survival using national-level data from the Netherlands Cancer Registry (NCR) for first-line treatments from 2016–2020. Additionally, we performed a secondary analysis using data from the Oncological Life Study (OncoLifeS) for any-line treatments. Descriptive statistics and annual percentage change (APC) assessed trends in patient and treatment characteristics. Overall survival analyses were performed. Results In the Netherlands (2016–2020) the proportion of first-line ICI-treated NSCLC patients significantly increased from 1.1–54.9% (APC = 14.5%, p = 0.002), replacing chemotherapy monotherapy. Stage III ICI-treated patients' proportion increased (APC = 3.5%, p = 0.034), while the proportion of ICI-treated patients with ≥ 50% PD-L1 expression decreased (APC=-13.82%, p = 0.039). 2-year overall survival (OS) was 25.9%. Median OS increased from 2016 to 2018 (16.6 to 19.4 months) and declined in 2019 and 2020 (17.3 and 16.6 months, respectively). In the secondary analysis, median OS varied by treatment line, being 18.8, 9.4 and 7.5 months for first-, second- and third-line treated patients respectively. Conclusion Using real-world data, we determined that ICI-based therapies replaced chemotherapy-only schemes as first-line treatment for NSCLC. Our survival data is comparable with data from RCTs on first-line ICI-treated NSCLC. The decreased survival over time may be attributed to the proportional decrease of individuals with ≥ 50% PD-L1 expression in treatment regimens. Further-line treatments are associated with lower survival.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know